NanoViricides Reports Significant Progress in Measles Treatment with NV-387

NanoViricides, Inc. (NYSE American: NNVC) has reported encouraging outcomes for NV-387, its forefront drug candidate, in combating Measles through a humanized animal study. The research demonstrated a remarkable 130% enhancement in survival rates among humanized mice subjected to a lethal respiratory infection model, extending survival from 7.4 to 17 days without any signs of toxicity and exhibiting dose-dependent effectiveness. NV-387 operates by imitating human cell characteristics to attach and deactivate viruses, aiming at more than 90% of human pathogens. This development is particularly critical given the global uptick in Measles incidents and the decreasing vaccine coverage, underscoring the dire necessity for a viable treatment alternative. Anil R. Diwan, PhD, expressed optimism about NV-387's trajectory towards becoming the inaugural Measles treatment drug.